Citius Oncology, Inc.
Stock Chart, Company Information, and Scan Results
$0.65(as of Apr 1, 4:00 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Citius Oncology, Inc. Company Information, Fundamentals, and Technical Indicators
Stock Price$0.65
Ticker SymbolCTOR
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
EmployeesUnknown
CountyUSA
Market Cap$54.7M
EBIDTAUnknown
P/E Ratio-2.40
Forward P/E Ratio35.59
Earnings per Share-0.31
Profit Margin-140.31%
RSI36.43
Shares Outstanding88.3M
ATR0.07
52-Week High6.19
Volume135,203
52-Week Low0.49
Book Value58.4M
P/B Ratio0.97
Upper Keltner0.91
P/S Ratio14.37
Lower Keltner0.58
Next Earnings DateUnknown
Cash Surplus-37.4M
Next Ex-Dividend DateUnknown
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Citius Oncology, Inc. In Our Stock Scanner
As of Apr 02, 2026
Scan Name: Hammer CandleScan Type: Candlestick Pattern Scans
As of ---
Scan Name: Dragonfly DojiScan Type: Candlestick Pattern Scans
As of ---
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.